Awaiting product image

Mesna Injection

Product/Composition Mesna Injection
Strength 400mg/4ml
Form Injection
Production Capacity 1 Million Injection/Month
Therapeutic use Anti Cancer
Package Insert/Leaflet Available upon request

INQUIRE ABOUT Mesna Injection

Mesna Injection is a protective agent used in chemotherapy to prevent or reduce the toxic effects of certain drugs, particularly hemorrhagic cystitis caused by cyclophosphamide or ifosfamide. It does not have anticancer activity itself but works by neutralizing harmful metabolites.

Here are the key details:

1. Composition and Form

  • Active ingredient: Mesna (sodium 2-mercaptoethanesulfonate).

  • Supplied as a sterile solution for intravenous (IV) or sometimes intramuscular (IM) use.

  • Administered under medical supervision, often in oncology settings.

2. Mechanism of Action

  • Chemotherapy drugs like cyclophosphamide and ifosfamide are metabolized to acrolein, which can irritate the bladder lining.

  • Mesna binds to acrolein in the urine, forming a non-toxic compound that is excreted in urine.

  • Reduces risk of hemorrhagic cystitis (bladder bleeding) without affecting chemotherapy efficacy.

3. Indications

  • Prevention of hemorrhagic cystitis during high-dose cyclophosphamide or ifosfamide therapy.

  • Often used in high-risk chemotherapy protocols where bladder toxicity is a concern.

4. Administration

  • Administered intravenously, usually before and during chemotherapy (sometimes with oral supplementation depending on protocol).

  • Dose is typically a fraction of the chemotherapeutic drug dose, adjusted by body surface area.

  • Timing is critical: Mesna must be present in the urine while toxic metabolites are excreted.

5. Side Effects

  • Generally well tolerated.

  • Common: mild nausea, vomiting, headache, flushing, fever.

  • Less common: dizziness, rash, injection-site reactions.

  • Rare: hypersensitivity reactions, hypotension if infused too rapidly.

6. Contraindications

  • Known hypersensitivity to Mesna or any component of the formulation.

7. Precautions

  • Ensure adequate hydration to maintain urine output during chemotherapy.

  • Monitor renal function in patients with impaired kidney function.

  • Adjust dose if urine output is low to ensure protective effect.

  • Do not mix with chemotherapy drugs in the same IV line unless compatibility is confirmed.

8. Storage

  • Store at controlled room temperature or as per manufacturer instructions.

  • Protect from light.

  • Use aseptically and discard unused portions according to guidelines.